Texas MPN Workshop 2020 | COVID-19 and MPN
John Mascarenhas, MD, of the Icahn School of Medicine at Mount Sinai, New York, NY, outlines the the impact of COVID-19 on the treatment and management of patients with myeloproliferative neoplasms (MPNs), including reducing nosocomial infection risk in myelofibrosis patients, changes in clincial trial enrollment, as well as highlighting a role of ruxolitinib in this indication. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Disclosures
John Mascarenhas, MD, has done consultancy work with Celgene/BMS, Prelude, Galecto, Promedior, Geron, Constellation and Incyte, and has received research funding from Incyte, Kartos, Roche, Promedior, Merck, Merus, Arog, CTI Biopharma, Janssen and PharmaEssentia.
